LFST LifeStance Health Group, Inc. Insider Trading

Director Robert Bessler sells 894,337 shares at $10.13 under 10b5-1 plan; holdings fall 57.7% to 656.6K shares

Robert Bessler, a director at LifeStance Health Group, Inc., executed 2 separate sales totaling 894,337 shares for $9,059,633.81 at a blended average price of $10.13 on 2026-06-26. His post-transaction holdings fell to 656,560 shares, a net reduction of 57.7% versus his pre-transaction position of 1,550,897 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The current stock price stands at $10.71, slightly below the 52-week high of $10.89, with the stock up 38.9% over 30 days and 68.1% over 90 days. At this ticker, Bessler's two prior sales on 2026-05-12 each posted a 30-day return of +7.4%. The scheduled nature of this sale precludes any characterization based on timing; investors should note the substantial reduction in Bessler's personal stake.

Director Bessler sells 575,034 shares of LFST at $8.02 for $4.6M, retaining 1.10M shares near 52-week high.

Director Robert Bessler sold 575,034 shares at $8.02, generating $4,611,772.68 in proceeds, while the stock's current price of $7.89 sits -11.2% below its 52-week high of $8.89. The sale occurred against a backdrop of notable recent price strength — the stock gained +21.2% over the prior 30 days — placing the transaction near the upper end of LFST's trading range. Despite the sizable disposal, Bessler retains 1,103,729 shares post-transaction, indicating continued meaningful economic exposure to the company. Investors may watch whether this sale, executed close to the 52-week high amid a strong near-term rally, reflects a near-peak disposition, particularly given LFST's elevated P/E of 131.50 relative to its $14.2M net income on $403.5M in quarterly revenue.

Darren M. Black sold 5.90M LFST shares at $8.02 (5/12/26) for $47.3M, retaining 23.31M shares; stock now at $7.89.

Director Darren M. Black executed a substantial $47.3M sale of 5,899,661 shares at $8.02 on 2026-05-12, reducing his position by 20% while still maintaining significant ownership of 23.31M shares. His prior three sales at LFST show poor timing: each post-sale period saw the stock rise (30d returns of -9.1%, +1.6%, and -10.2%; 90d returns of +15.6%, +26.2%, and +2.2%), with a 0% well-timed rate at the 90-day mark. The current price of $7.89 is below the $8.02 sale price and 11.2% below the 52-week high, though the stock has gained 21.2% over the past 30 days. Given the company's high P/E of 131.50, revenue growth of 13.8%, and his consistent pattern of selling into rallies that subsequently continue higher, this sale provides a signal worth monitoring but does not yet indicate a structural conviction shift by an insider with a demonstrated track record of sub-optimal exit timing.

TPG GP A, LLC sells 28.28M LFST shares ($226.8M) at $8.02; remains top holder with 111.74M shares post-sale

TPG GP A, LLC's substantial sale of 28,281,943 shares for $226,821,182.86 represents a meaningful but measured reduction by a 10% owner, leaving it as a dominant stakeholder with 111,744,614 shares remaining. Despite the large dollar volume, the sale occurred when stock was -11.2% from its 52-week high of $8.89, and the current price of $7.89 sits slightly below the $8.02 sale price—neither an obvious peak exit nor a distressed sale. The seller's track record shows limited success timing sales (22.22% well-timed rate on 13 prior sells), and LFST's fundamentals remain mixed: strong revenue growth at +13.8% annually but challenged valuation at P/E 131.50 with thin net income of $14.2M on $403.5M in revenue. The sale signals capital deployment activity by a major shareholder but does not necessarily reflect loss of confidence, given the retained 111.74M-share position.

Director BLACK DARREN M. sold 4,314,939 shares of LFST at $7.01 on 2026-03-02 for $30,247,722.39; reduced stake by 12.9%.

Director BLACK DARREN M. executed a substantial sale of 4,314,939 shares at $7.01, reducing his holdings from 33,524,715 shares to 29,209,776 shares—a 12.9% reduction of his pre-transaction stake. The sale occurred at a price -10.2% from the 52-week high of $8.16, and the stock currently trades at $7.33, 4.6% above the transaction price. His prior two sales at LFST both generated positive 90-day returns (+1.6% and +26.2%), meaning both prior sales preceded stock appreciation—a pattern of poorly-timed exits at this ticker. The company's fundamentals show revenue of $363,809,000.00 with net income of $1,077,000.00, a P/E of 48.87, and annual revenue growth of +13.8%, reflecting modest profitability relative to valuation. The substantial dollar magnitude ($30,247,722.39) and the substantial portion of holdings disposed signal a material reduction in the director's financial commitment to the company.

TPG GP A, LLC sold 20,685,061 shares of LFST at $7.01 on 2026-03-02, reducing stake to 140,026,557 shares (-12.9%).

TPG GP A, LLC, a 10% owner of LifeStance Health Group, Inc., executed a substantial sale of 20,685,061 shares at $7.01, reducing its holdings by 12.9% to 140,026,557 shares. The transaction value was $145,002,277.61. The sale occurred at a price -10.2% below the 52-week high of $8.16, while the current stock price of $7.33 is 4.6% above the transaction price. Cross-ticker, the insider's 13 prior sells showed a well-timed rate of 33.33%, suggesting mixed execution timing on divestments. At this specific ticker, a prior sale in May 2024 was poorly timed (90-day return +2.2%), indicating no consistent predictive advantage in LFST holdings. LifeStance reported quarterly revenue of $363,809,000.00, net income of $1,077,000.00, and annual revenue growth of +13.8%, trading at a P/E of 48.87 with a market cap of $2,857,110,929.30.

Silversmith Partners I GP sells 3,592,357 LFST shares at $5.07; exit trims 20.1% of stake as stock trades 34.5% below 52-week high.

Silversmith Partners I GP sold 3,592,357 shares of LifeStance Health on 2025-08-18 at $5.07, reducing its stake by 20.1% to 14,324,197 shares. The sale occurred at a significant discount: the stock currently trades at $5.35, down 34.5% from its 52-week high of $8.17, though it has recovered 28.3% over the past 30 days. Notably, the insider's prior sell at this same ticker on 2024-05-24 was poorly timed, as the stock subsequently posted a 90-day return of 2.2%—meaning the insider sold before a gain, not a decline. LFST remains unprofitable (net income $-3.8M in the latest quarter), though the company shows strong revenue growth of 18.5% year-over-year on a base of $345.3M quarterly revenue. The partial divestiture in a depressed price environment, combined with the historical pattern of mistimed sells at this ticker, warrants attention to whether Silversmith's liquidity needs or confidence in the recovery may be driving the decision.

Director Darren M. Black sold 8,407,643 shares (8.41M) of LFST at $5.07; now holds 33,524,715 shares post-sale.

Director Darren M. Black sold 8,407,643 shares representing a 20.1% reduction in his LFST holdings on 2025-08-18 at $5.07. The transaction occurred when the stock trades 34.5% below its 52-week high of $8.17, though it has rebounded 28.3% over the past 30 days. LifeStance remains unprofitable (net income of $-3,791,000 in the latest quarter) despite 18.5% annual revenue growth, indicating the company is still in a loss-making phase. His prior LFST sale in May 2024 at the same price point ($5.07 equivalent basis) subsequently rose 2.2% over 90 days, suggesting that previous sale was not well-timed; the current sale's timing relative to future price action will depend on whether the company's path to profitability materializes or further deteriorates.

Summit Partners L P sold 8,407,643 shares (8.41M) of LFST at $5.07 on 2025-08-18, reducing stake by 20.1% to 33,524,715 shares remaining.

Summit Partners L P, a 10% owner, executed a substantial open-market sale of 8,407,643 shares at $5.07, representing a -20.1% reduction in holdings and valued at $42,626,750.01. The sale occurred at a price 5.2% below the current market price of $5.35 and 38.0% below the 52-week high of $8.17, reflecting the stock's sharp downward trajectory over the past 90 days (-5.0%). LifeStance Health remains unprofitable on a full-year basis (net income $-3,791,000.00 in the latest quarter) despite quarterly revenue of $345,311,000.00 and annual growth of 18.5%, creating a mismatch between growth and profitability that may inform large-holder strategic repositioning. The timing context is mixed: across all tickers, Summit's 18 prior sells averaged a 90-day well-timed rate of 18.75%, but at LFST specifically, its single prior sale on 2024-05-24 was poorly timed (90d return +2.2%), and this current sale comes during a period of modest 30-day recovery (+28.3%) following a broader 90-day decline, which offers limited clarity on forward-price expectations.

Director Burdick purchased 114,181 shares at blended average $4.36, totaling $498,293.90; stock down 43.0% from 52-week high.

Kenneth A Burdick, a Director at LifeStance Health Group, executed 5 separate purchases totaling 114,181 shares for $498,293.90 at an average price of $4.36 per share across two trading days (2025-08-08 and 2025-08-11). The current stock price of $4.66 reflects a decline of 43.0% from the 52-week high of $8.17, placing the purchase near depressed price levels. LifeStance reported negative net income of $-3,791,000 in its latest quarter and was unprofitable over its most recent full fiscal year, though the company showed revenue growth of 18.5% year-over-year. Burdick's single prior sale at LFST (2024-03-15) produced negative 90-day returns, demonstrating a historically well-timed exit pattern; however, his current multi-transaction buy program during a period of stock weakness and company losses does not necessarily represent market-timing skill and requires evaluation in the context of any pre-arranged trading plans or scheduled investments.